Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H1 2016', provides an overview of the Secondary (Hypogonadotropic) Hypogonadism pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Secondary (Hypogonadotropic) Hypogonadism and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Secondary (Hypogonadotropic) Hypogonadism
- The report reviews pipeline therapeutics for Secondary (Hypogonadotropic) Hypogonadism by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Secondary (Hypogonadotropic) Hypogonadism therapeutics and enlists all their major and minor projects
- The report assesses Secondary (Hypogonadotropic) Hypogonadism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Secondary (Hypogonadotropic) Hypogonadism


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Secondary (Hypogonadotropic) Hypogonadism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Secondary (Hypogonadotropic) Hypogonadism Overview 6
Therapeutics Development 7
Pipeline Products for Secondary (Hypogonadotropic) Hypogonadism - Overview 7
Pipeline Products for Secondary (Hypogonadotropic) Hypogonadism - Comparative Analysis 8
Secondary (Hypogonadotropic) Hypogonadism - Therapeutics under Development by Companies 9
Secondary (Hypogonadotropic) Hypogonadism - Therapeutics under Investigation by Universities/Institutes 10
Secondary (Hypogonadotropic) Hypogonadism - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Secondary (Hypogonadotropic) Hypogonadism - Products under Development by Companies 13
Secondary (Hypogonadotropic) Hypogonadism - Products under Investigation by Universities/Institutes 14
Secondary (Hypogonadotropic) Hypogonadism - Companies Involved in Therapeutics Development 15
Forendo Pharma Limited 15
Merck & Co., Inc. 16
Mereo Biopharma Group Limited 17
Millennium Pharmaceuticals, Inc. 18
Repros Therapeutics Inc. 19
Secondary (Hypogonadotropic) Hypogonadism - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
BGS-649 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
corifollitropin alfa - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
enclomiphene citrate - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
fispemifene - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Kisspeptin-10 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
MSS-722 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
TAK-448 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
testosterone undecanoate - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Secondary (Hypogonadotropic) Hypogonadism - Recent Pipeline Updates 40
Secondary (Hypogonadotropic) Hypogonadism - Dormant Projects 55
Secondary (Hypogonadotropic) Hypogonadism - Discontinued Products 56
Secondary (Hypogonadotropic) Hypogonadism - Product Development Milestones 57
Featured News & Press Releases 57
Mar 28, 2016: Apricus Reports Top-Line Phase 2b Data for Fispemifene in Symptomatic Secondary Hypogonadism 57
Mar 15, 2016: Repros Announces Initiation of Formal Approval Process by the European Medicines Agency 57
Feb 16, 2016: Repros Completes Randomization of Enclomiphene Phase 2 Proof of Concept Study in Obese Secondary Hypogonadal Men 58
Feb 08, 2016: Repros Holds Meeting With FDA to Discuss Complete Response Letter for Enclomiphene in the Treatment of Secondary Hypogonadism 59
Feb 02, 2016: Apricus Biosciences to Present at the 18th Annual BIO CEO & Investor Conference and Provide Update on Fispemifene 59
Jan 11, 2016: Repros Announces Court of Appeals' Affirmation of Summary Judgment in Favor of the Company 59
Jan 04, 2016: Repros Updates Enclomiphene Program 60
Dec 01, 2015: Repros Therapeutics Receives Complete Response Letter From FDA for Enclomiphene 60
Dec 01, 2015: Apricus Biosciences Confirms Clinical Strategy for Its Novel Treatment for Symptomatic Secondary Hypogonadism Fispemifene 60
Oct 29, 2015: Repros Therapeutics Announces Cancellation of FDA Advisory Committee Meeting to Review Enclomiphene for the Treatment of Secondary Hypogonadism 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63

List of Tables

Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, H1 2016 7
Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Products under Investigation by Universities/Institutes, H1 2016 14
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Forendo Pharma Limited, H1 2016 15
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Merck & Co., Inc., H1 2016 16
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Mereo Biopharma Group Limited, H1 2016 17
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 18
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Repros Therapeutics Inc., H1 2016 19
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Stage and Target, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 24
Number of Products by Stage and Route of Administration, H1 2016 26
Number of Products by Stage and Molecule Type, H1 2016 28
Secondary (Hypogonadotropic) Hypogonadism Therapeutics - Recent Pipeline Updates, H1 2016 40
Secondary (Hypogonadotropic) Hypogonadism - Dormant Projects, H1 2016 55
Secondary (Hypogonadotropic) Hypogonadism - Discontinued Products, H1 2016 56